<DOC>
	<DOCNO>NCT02395068</DOCNO>
	<brief_summary>Nimotuzumab IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) , inhibit tyrosine kinase activation . It approve treat squamous cell carcinoma head neck ( SCCHN ) , glioma nasopharyngeal carcinoma different country . Currently , register clinical trial Nimotuzumab combine chemotherapy advance non-small cell lung cancer , colorectal cancer , esophageal cancer glioma approve ongoing investigator ' country . The main purpose study evaluate pharmacokinetic characteristic Nimotuzumab combine Irinotecan patient solid tumor .</brief_summary>
	<brief_title>Pharmacokinetics Study Nimotuzumab Patients With Solid Tumors</brief_title>
	<detailed_description>This single-centered , non-randomized open-labeled Clinical Pharmacokinetics Study Nimotuzumab patient solid tumor . The test include 3 dose group , namely Single dose group , Multiple single-week dose group Multiple bi week dose group , evaluate pharmacokinetic characteristic Nimotuzumab combine Irinotecan patient solid tumor .</detailed_description>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Inclusion criterion : 1 . Confirmed pathology / cytology diagnosis patient advance solid tumor 2 . Failure firstline multiline chemotherapy suitable irinotecan therapy 3 . Age 1870 year , gender enrollment 4 . ECOG 0 1 5 . Adequate bone marrow function 6 . Recover toxicity previous treatment 7 . At least one measurable site disease define least 20mm great dimension CT 10mm great dimension SCT/MRI 8 . Male female fertility trial willing take contraceptive measure 9 . Estimated life expectancy 3 month great 10 . All patient sign write informed consent Exclusion criterion : 1 . Have previously receive EGFRtargeted therapy 2 . Current treatment effective program 3 . Participated clinical trial within 4 week enrollment 4 . Nervous system symptom cause brain metastasis need apply steroidal antiedema medication control 5 . Persistent uncontrollable diarrhea CTCAE 2 level ( 46 time daily ) 6 . Complete incomplete intestinal obstruction 7 . Need drainage pleural effusion ascites 8 . Drug addiction adverse longterm alcoholic , well AIDS patient 9 . Occurred myocardial infarction within 6 month 10 . Diagnosed severe interstitial pneumonitis pulmonary fibrosis Chest CT 11 . Severe uncontrolled complication , infection require systemic treatment，fever（≥38℃），congestive heart failure，diabetes hypertension control drug complication may interfere drug efficacy 12 . Drug allergy（≥CTCAE 3.0） , shock allergy symptom , especially allergic similar drug past severe hypersensitivity polysorbate eightycontaining drug 13 . Uncontrollable seizure loss insight psychosis 14 . Female patient pregnant , breastfeeding , childbearing potential take contraceptive measure 15 . Male patient want spouse pregnant trial 16 . Researchers believe participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Nimotuzumab</keyword>
	<keyword>Safety</keyword>
	<keyword>Effcacy</keyword>
	<keyword>Irinotecan</keyword>
</DOC>